Figure S3. Knockdown of KDM6A or KDM6B enhances cisplatin-induced apoptosis in OS cells. Cleaved Caspase 3 expression in KDM6A- or KDM6B-knockdown and control OS cells with cisplatin treatment. (TIF 147 kb
Combined inhibition of human epidermal growth factor receptor-2 (HER2), p110Îą and Vps34 induces cel...
Figure S2. The effect of IMB0901 combined with cisplatin (A) or gemcitabine (B) on the cell survival...
Figure S3. Fn14 inhibits cisplatin resistance in HGSOC primary cancer cells with p53-R248Q. (A)-(D) ...
Figure S2. Knockdown efficacy of KDM6A and KDM6B as measured by western blot analysis. (TIF 217 kb
Figure S1. mRNA expression of methyltransferases and demethylases in OS cells with or without cispla...
Figure S4. Upregulation of H3K27me3 levels sensitizes OS to cisplatin. Colony formation ability of O...
Figure S5. Overexpression of PRKCA reverses the chemosensitization effects of GSK-J4 with regards to...
Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
MTT assay of combination of RTK inhibitors with cisplatin. Influence of 48 h preincubation with 1.5 ...
Figure S1. ETS-1 is important for cisplatin sensitive HNSCC cell proliferation. Figure S2. ETS-1 is ...
SP differentiation assay for evaluation of CSC enrichment in TOV21G and SKOV3. A & B. Quantification...
Figure S1. (A) KLF4 WT or KO PC3 cells were treated with 20Â ÎźM cisplatin at the indicated times. G...
Combined inhibition of human epidermal growth factor receptor-2 (HER2), p110Îą and Vps34 induces cel...
Figure S2. The effect of IMB0901 combined with cisplatin (A) or gemcitabine (B) on the cell survival...
Figure S3. Fn14 inhibits cisplatin resistance in HGSOC primary cancer cells with p53-R248Q. (A)-(D) ...
Figure S2. Knockdown efficacy of KDM6A and KDM6B as measured by western blot analysis. (TIF 217 kb
Figure S1. mRNA expression of methyltransferases and demethylases in OS cells with or without cispla...
Figure S4. Upregulation of H3K27me3 levels sensitizes OS to cisplatin. Colony formation ability of O...
Figure S5. Overexpression of PRKCA reverses the chemosensitization effects of GSK-J4 with regards to...
Characterization of MDA-MB231 and cisplatin-resistant MDA-MB231CisR. MDA-MB231 and cisplatin-resista...
NF-κB escalated PIK3CA promoter activity in SP cells. Cisplatin and TNFα but not lithium chloride or...
List of protein identified exclusively in A2780-CisR control (untreated) cells. Table S2. List of pr...
Cisplatin induced NF-κB and its physical interaction with PIK3CA promoter in TOV21G and SKOV3 cells....
MTT assay of combination of RTK inhibitors with cisplatin. Influence of 48 h preincubation with 1.5 ...
Figure S1. ETS-1 is important for cisplatin sensitive HNSCC cell proliferation. Figure S2. ETS-1 is ...
SP differentiation assay for evaluation of CSC enrichment in TOV21G and SKOV3. A & B. Quantification...
Figure S1. (A) KLF4 WT or KO PC3 cells were treated with 20Â ÎźM cisplatin at the indicated times. G...
Combined inhibition of human epidermal growth factor receptor-2 (HER2), p110Îą and Vps34 induces cel...
Figure S2. The effect of IMB0901 combined with cisplatin (A) or gemcitabine (B) on the cell survival...
Figure S3. Fn14 inhibits cisplatin resistance in HGSOC primary cancer cells with p53-R248Q. (A)-(D) ...
DOI
Add to ORKG